Literature DB >> 30793542

AMH and INSL3 in testicular and extragonadal pathophysiology: what do we know?

A Sansone1,2, S Kliesch1, A M Isidori2, S Schlatt1.   

Abstract

BACKGROUND: It is commonly accepted that testicular function is prevalently regulated by the hypothalamic-pituitary-gonadal axis: The pulsatile secretion of GnRH by the hypothalamus induces pituitary expression of the two gonadotropins FSH and LH, which then stimulate Sertoli and Leydig cells, respectively, therefore regulating steroidogenesis and spermatogenesis. However, a growing body of evidence has recently suggested that other hormones act on the reproductive tract since the early phases of fetal development. Anti-Müllerian hormone and INSL3 are still largely used only for research purposes despite being increasingly recognized as markers of Sertoli and Leydig cells function, respectively.
OBJECTIVES: Provide an up-to-date review of the role of anti-Müllerian hormone and INSL3 in human pathophysiology according to current evidence.
MATERIALS AND METHODS: A thorough literature review was performed on PubMed, OVID MEDLINE/EMBASE and Google Scholar for papers concerning anti-Müllerian hormone and INSL3 in human males.
RESULTS: INSL3 is not acutely regulated by the hypothalamic-pituitary axis but is constitutively secreted by Leydig cells, therefore representing a valid marker for their number and status. Anti-Müllerian hormone expression, on the other hand, is downregulated by androgens, therefore occurring mostly at the early stages of testicular differentiation and before the onset of puberty. Several conditions affecting testicular development, such as male hypogonadotropic hypogonadism, and their treatment have been associated to specific pattern of INSL3 and anti-Müllerian hormone expression, proving a role for both hormones in the diagnostic and therapeutic management. Recent reports suggest a role for both anti-Müllerian hormone and INSL3 in extra gonadal physiology, such as cardiovascular and bone health.
CONCLUSION: Anti-Müllerian hormone and INSL3 are markers of Sertoli and Leydig cells maturation, respectively, usually involved in the pathogenesis of disorders of sexual differentiation. However, their role in testicular pathology has only been hinted at in the last decades. Recent evidence supports an involvement of both anti-Müllerian hormone and INSL3 in extragonadal pathophysiology as well.
© 2019 American Society of Andrology and European Academy of Andrology.

Entities:  

Keywords:  AMH; INSL3; Müllerian ducts; cryptorchidism; testicular development; testis

Mesh:

Substances:

Year:  2019        PMID: 30793542     DOI: 10.1111/andr.12597

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   3.842


  16 in total

1.  Targeted disruption of galectin 3 in mice delays the first wave of spermatogenesis and increases germ cell apoptosis.

Authors:  Tao Lei; Sandra M Blois; Nancy Freitag; Martin Bergmann; Sudhanshu Bhushan; Eva Wahle; Annie Chi-Chun Huang; Hung-Lin Chen; Michaela F Hartmann; Stefan A Wudy; Fu-Tong Liu; Andreas Meinhardt; Monika Fijak
Journal:  Cell Mol Life Sci       Date:  2021-01-28       Impact factor: 9.261

2.  Sertoli and Germ Cells Within Atrophic Seminiferous Tubules of Men With Non-Obstructive Azoospermia.

Authors:  Christian Fuglesang Skjødt Jensen; Danyang Wang; Linn Salto Mamsen; Aleksander Giwercman; Niels Jørgensen; Mikkel Fode; Dana Ohl; Lihua Dong; Simone Engmann Hildorf; Susanne Elisabeth Pors; Jens Fedder; Elissavet Ntemou; Claus Yding Andersen; Jens Sønksen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-02       Impact factor: 6.055

3.  Gonadal sex steroid hormone secretion after exposure of male rats to estrogenic chemicals and their combinations.

Authors:  B O Jeminiwa; R C Knight; K L Abbot; S R Pondugula; B T Akingbemi
Journal:  Mol Cell Endocrinol       Date:  2021-05-24       Impact factor: 4.369

4.  Immunohistochemical characterization of the anti-Müllerian hormone receptor type 2 (AMHR-2) in human testes.

Authors:  A Sansone; A M Isidori; S Kliesch; S Schlatt
Journal:  Endocrine       Date:  2020-02-06       Impact factor: 3.633

5.  Performance characteristics of the Mindray chemiluminescence anti-Müllerian hormone assay.

Authors:  Jing-Jing Zhao; Chun-Min Kang; Peng Zhang; Lei Zheng
Journal:  J Clin Lab Anal       Date:  2021-03-04       Impact factor: 2.352

6.  Effects of Midazolam on the Development of Adult Leydig Cells From Stem Cells In Vitro.

Authors:  Xingyi Zhao; Minpeng Ji; Xin Wen; Dan Chen; Fu Huang; Xiaoju Guan; Jing Tian; Jiajia Xie; Jingjing Shao; Jiexia Wang; Luoqi Huang; Han Lin; Leping Ye; Haolin Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-12       Impact factor: 5.555

Review 7.  Effects of endocrine disruptors on fetal testis development, male puberty, and transition age.

Authors:  Francesco Cargnelutti; Andrea Di Nisio; Francesco Pallotti; Iva Sabovic; Matteo Spaziani; Maria Grazia Tarsitano; Donatella Paoli; Carlo Foresta
Journal:  Endocrine       Date:  2020-08-05       Impact factor: 3.633

8.  Anti-Müllerian hormone and letrozole levels in boys with constitutional delay of growth and puberty treated with letrozole or testosterone.

Authors:  E Kohva; T Varimo; H Huopio; S Tenhola; R Voutilainen; J Toppari; P J Miettinen; K Vaaralahti; J Viinamäki; J T Backman; M Hero; T Raivio
Journal:  Hum Reprod       Date:  2020-02-29       Impact factor: 6.918

Review 9.  New insights into anti-Müllerian hormone role in the hypothalamic-pituitary-gonadal axis and neuroendocrine development.

Authors:  Mauro S B Silva; Paolo Giacobini
Journal:  Cell Mol Life Sci       Date:  2020-06-20       Impact factor: 9.261

10.  Aging, inflammation and DNA damage in the somatic testicular niche with idiopathic germ cell aplasia.

Authors:  Massimo Alfano; Anna Sofia Tascini; Filippo Pederzoli; Irene Locatelli; Manuela Nebuloni; Francesca Giannese; Jose Manuel Garcia-Manteiga; Giovanni Tonon; Giada Amodio; Silvia Gregori; Alessandra Agresti; Francesco Montorsi; Andrea Salonia
Journal:  Nat Commun       Date:  2021-09-01       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.